Xperi Inc. (XPER) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Technology / Software · as of Aug 12, 2026
Xperi Inc. (XPER)
A forensic read on Xperi Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-1.9
Distress distance
Clean
Earnings quality
6
Forensic signals
-14.0
P / E (ttm)
-13.6%
ROE
$323M
Market cap
0.00%
Dividend yield
-9.2%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Xperi Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -1.9, placing it in the Distress zone. 6 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-8.5%
FY2025
Return on invested capital.Return on invested capital is -8.5% in the latest fiscal year and rising from -139% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+3.0%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +9% over the last 3 years to FY2025 (+3.0%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~3.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~8%.
stopped
FY2024→FY2025
Shareholder returns — halted.Capital returns have STOPPED — $20M of buybacks + dividends in FY2024, but ~$0 in FY2025. A halt usually means the company is conserving cash.
47d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 42 to 47 days FY2024→FY2025 (receivables -3% vs revenue -9%). Receivables are creeping up relative to sales. Across FY2023–FY2025 the day count ran 42 → 42 → 47 days, so the latest reading sits on top of a record that was flat or falling before it — one year's move, not a direction the business has been travelling in.
9% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 9% of revenue in FY2025 — about $0.89 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count, and there it has run at about 3.0% a year and is falling.
Key fundamentals
Latest Revenue$448.1M
Revenue Growth YoY-9.2%
Revenue CAGR (3yr)-3.7%
Net Margin-12.6%
Free Cash Flow-$5.9M
Return on Equity-13.6%
Debt / Equity0.10x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Xperi Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Aug 12, 2026. Forensic signals flag probability, not certainty.
$605M
FY2022–FY2022
Goodwill impairments.Took $605M of goodwill writedowns across 1 year (FY2022 ($605M)). Writedowns mean past acquisitions underperformed what was paid for them.